CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase II Study of Dexamethasone (DECADRON®), Thalidomide (THALOMID®), and Lenalidomide (REVLIMID®) for Subjects With Relapsed or Refractory Multiple Myeloma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT00538824
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:36:54.770209+00:00
Published At: 2017-06-08T00:00:00+00:00
Record Updated At: 2018-06-06
Results Posted At: 2017-06-08
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Multiple Myeloma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2018-06-06"
protocolSection.identificationModule.nctId: "NCT00538824"
protocolSection.identificationModule.officialTitle: "A Phase II Study of Dexamethasone (DECADRON\u00ae), Thalidomide (THALOMID\u00ae), and Lenalidomide (REVLIMID\u00ae) for Subjects With Relapsed or Refractory Multiple Myeloma"
protocolSection.statusModule.overallStatus: "TERMINATED"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2017-06-08"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.